Form 4: Immunovant's Chief Legal Officer Sells Shares to Cover Tax Obligations

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold 4,361 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Mark S. Levine, the Chief Legal Officer of Immunovant, Inc., reported the sale of 4,361 shares of common stock on October 23, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of 8,937 restricted stock units (RSUs) on October 19, 2024.
• The shares were sold at a weighted average price of $29.53, with individual transactions ranging from $29.38 to $29.68 per share.
• Following the transaction, Levine directly owns 322,878 shares of Immunovant common stock.
• The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction.

Sentiment

Score: 5

Explanation: This is a routine transaction related to tax obligations and doesn't reflect a significant change in sentiment towards the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives. This transaction is a routine event and doesn't necessarily indicate a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a common occurrence across publicly traded companies.
• Companies like Pfizer, Johnson & Johnson, and Merck also see similar transactions by their executives related to RSU vesting.
• The 'sell to cover' method is a standard practice to manage tax obligations, ensuring executives can meet their financial responsibilities without needing to liquidate other assets.

Stakeholder Impact

• The transaction has minimal impact on shareholders as it is a routine sale to cover tax obligations.
• Employees are not directly affected by this transaction.

Key Dates